Summary

securechain3 Users

  • How does nintedanib overcome cancer drug-resistant mutation regarding RET protein-tyrosine kinase: experience coming from molecular characteristics models.
Offline Offline
Posts:
0 (0 per day)
Age:
N/A
Date Registered:
2025-08-13, 01:05:01
Local Time:
2025-08-31, 05:14:22
Last Active:
2025-08-13, 03:18:11
Signature:
6% for the total omentectomy group (log-rank P= .06; hazard ratio 0.7 [95% confidence interval, 0.48-1.01]). #link# The 5-year relapse-free survival w